Caffeine Supplementation, Resistance Training and Blood Antioxidant Status

Caffeine Clinical Trial

Official title:

Acute Effects of Caffeine Supplementation on Resistance Training Volume and Blood Antioxidant Status in Resitance Trained Men

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05230303
• Other study ID #: 01_2021
• Status: Completed
• Phase: N/A
• Start date: January 12, 2022
• Est. completion date: January 31, 2023

Study information

• Verified date: March 2023
• Source: The Jerzy Kukuczka Academy of Physical Education in Katowice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to verify the effect of acute caffeine intake on resistance training volume and blood antioxidant status, in a randomised, double-blind, placebo-controlled crossover trial.

Description:

Caffeine is one of the most commonly consumed psychoactive substances in the world. Several previous studies confirmed that caffeine improves several aspects of exercise performance, including resistance training outcomes. Interestingly, caffeine and its catabolic products, theobromine and xanthine, exhibit antioxidant and prooxidant properties. Additionally, resistance training promotes the generation of reactive oxygen species, which are important for the cellular adaptation process.

Hovewer, to the best of our knowledge, there is no information as to how caffeine combined with resistance training affects blood antioxidant status. Therefore, the aim of this study was to examine acute effects of caffeine supplementation on resistance training volume and blood antioxidant status in resistance trained men.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 31, 2023
• Est. primary completion date: January 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• written consent to participate,

• medical permission by physician

• "resistance-trained," defined as having a minimum of two years of resistance training experience

• minimum of 2 workout sessions per week in the last 6 months

Exclusion Criteria:

• neuromuscular or musculoskeletal disorders

• current injury

• using any medications, dietary supplements or ergogenic aids which could potentially affect the study outcomes

• a positive smoking status

• potential allergy to caffeine

Related Conditions & MeSH terms

• Caffeine

Intervention

Dietary Supplement:
• Caffeine supplementation
Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
• Placebo treatment
The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.

Locations

Country	Name	City	State
Poland	The Jerzy Kukuczka Academy of Physical Education	Katowice

Sponsors (1)

Lead Sponsor	Collaborator
The Jerzy Kukuczka Academy of Physical Education in Katowice

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change the levels of oxidative stress markers	Serum will be obtained for TOS/TOC (total oxidative stress), MDA (malondialdehyde), oncentration of TAS (total antioxidant status), activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx); concentartion of GSH (reduced glutathione) and UA (uric acid)	Day 1, Day 2
Primary	Changes in markers of muscle damage	Serum will be obtained for activity of creatine kinase (CK) and lactate dehydrogenase (LDH), concentration of myoglobin (Mb)	Day 1, Day 2
Primary	Changes in Inflammation markers	Serum will be obtained for level of interleukin 6, TNF alfa (tumor matrix factor), CRP (C-reactive protein)	Day 1, Day 2
Primary	Changes in markers of liver function	Serum will be obtained for activity of ASPAT (aspartate aminotransferase), ALAT (alanine aminotransferase) and gamma glutamyltransferase (GGT)	Day 1, Day 2
Secondary	Changes in resistance training volume		During caffeine and placebo treatment
Secondary	Changes in rate of perceived exertion after resistance training		Immediately after exercise protocol during caffeine and placebo treatment
Secondary	Changes in heart rate during resistance training		During caffeine and placebo treatment
Secondary	Changes in muscle soreness		prior to exercise, and 24, 48, 72, 96 and 120 hours post exercise.